PROSE Treatment in Atypical Ocular Graft-Versus-Host Disease

被引:11
|
作者
Chiu, Gloria B. [1 ]
Theophanous, Christos [1 ]
Irvine, John A. [2 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA
关键词
graft-versus-host disease (GvHD); persistent epithelial defects (PEDs); Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE); scleral lenses; systemic immunosuppression; SYSTEMIC MASTOCYTOSIS; SOLITARY MASTOCYTOMA;
D O I
10.1097/OPX.0000000000001003
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To report a case of persistent epithelial defects in a patient with ocular chronic graft-versus-host disease that required coordinated modulation of systemic immunosuppressive treatment and overnight wear of Prosthetic Replacement of the Ocular Surface Ecosystem (BostonSight PROSE, Needham, MA) devices to achieve ocular surface healing. Case Report. The case of a 38-year-old male patient who presented with a 2-year history of ocular chronic graft-versus-host disease, ocular burning, pain, light sensitivity, and a 3-week history of bilateral corneal epithelial defects is presented. Standard therapies and an initial PROSE treatment utilizing customized scleral lenses were unsuccessful in resolving his ocular complications. A second trial of PROSE treatment involving overnight wear of the devices in combination with increased systemic immunosuppressant therapy ultimately allowed ocular surface healing and improved his discomfort, vision, and quality of life. Conclusions. Sight-threatening complications of ocular chronic graft-versus-host disease often require a multidisciplinary approach. Persistent corneal epithelial defects may require increased systemic immunosuppression and extension of PROSE treatment to overnight wear.
引用
收藏
页码:1444 / 1448
页数:5
相关论文
共 50 条
  • [41] Prevention and treatment of graft-versus-host disease
    Chao, NJ
    Schlegel, PG
    BONE MARROW TRANSPLANTATION: FOUNDATIONS FOR THE 21ST CENTURY, 1995, 770 : 130 - 140
  • [42] Treatment of graft-versus-host disease with photopheresis
    Dall'Amico, R
    Zacchello, G
    TRANSPLANTATION, 1998, 65 (09) : 1283 - 1284
  • [43] Ruxolitinib for the treatment of graft-versus-host disease
    Ali, Haris
    Salhotra, Amandeep
    Modi, Badri
    Nakamura, Ryotaro
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2020, 16 (04) : 347 - 359
  • [44] Advances in the treatment of graft-versus-host disease
    GB Vogelsang
    Leukemia, 2000, 14 : 509 - 510
  • [45] Bilateral corneal ulceration in ocular graft-versus-host disease
    Stevenson, William
    Shikari, Hasanain
    Saboo, Ujwala S.
    Amparo, Francisco
    Dana, Reza
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 2153 - 2157
  • [46] Validation of Measurement Scales in Ocular Graft-versus-Host Disease
    Inamoto, Yoshihiro
    Chai, Xiaoyu
    Kurland, Brenda F.
    Cutler, Corey
    Flowers, Mary E. D.
    Palmer, Jeanne M.
    Carpenter, Paul A.
    Heffernan, Mary J.
    Jacobsohn, David
    Jagasia, Madan H.
    Pidala, Joseph
    Khera, Nandita
    Vogelsang, Georgia B.
    Weisdorf, Daniel
    Martin, Paul J.
    Pavletic, Steven Z.
    Lee, Stephanie J.
    OPHTHALMOLOGY, 2012, 119 (03) : 487 - 493
  • [47] Ocular findings in patients with chronic graft-versus-host disease
    Allan, E.
    Wu, M.
    Martin, P.
    Flowers, M.
    Bensinger, R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (01) : 181 - 182
  • [48] Ocular Graft-Versus-Host Disease After Allogeneic Transplantation
    Johnson, Natasha L.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2013, 17 (06) : 621 - 626
  • [49] Manifestation of Clinical Categories of Ocular Graft-versus-Host Disease
    Qiu, Yuan
    Hong, Jing
    Peng, Rongmei
    JOURNAL OF OPHTHALMOLOGY, 2018, 2018
  • [50] Evolving therapeutic paradigms in ocular graft-versus-host disease
    Masalkhi, Mouayad
    Wahoud, Noura
    Moran, Bridget
    Elhassadi, Ezzat
    EYE, 2024, 38 (17) : 3215 - 3217